Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Keeping Track: New Submissions In Bladder Cancer, HCV And Diabetes; Avastin Label Expands

Executive Summary

The latest drug development news and highlights from our FDA Performance Tracker.


Related Content

Sun Hit As US FDA Raises Fresh Concerns Over Key Halol Plant
'Brilliant' and 'Steady' Jenkins Retiring From US FDA's Office of New Drugs
Jardiance's Cardiovascular Benefit Claim Bodes Well For Other Products Too
Nearing Finish Line, HCV Race Focuses On Salvage Therapy
Gilead Coming To The End Of HCV Road With Triple-Drug Regimen
EASD 2016: Semaglutide Steals The Show With Impressive Cardiovascular Outcomes Data
Novo Will Go After MACE Indication For Victoza Based On LEADER
FDA Warning Eclipses Sun, SPARC But Investors Stand Pat
Does FDA's Elepsia CRL Signal Broader Compliance Woes For Sun Spin-off?
Avastin Ovarian Cancer Approval Brings Some Clarity On PFS Endpoint


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts